What We'll Be Watching at ASCO

ASCO’s almost here!

The annual meeting of the American Society of Clinical Oncology begins on June 3 in Chicago.  Fight Colorectal Cancer staff will be there, both in the Exhibit Hall with information about our work and attending scientific sessions to learn about the latest advances in colorectal cancer prevention and treatment.

ASCO Abstracts are available online for browsing.  We’ve been looking through them, hunting for the ones we think are important to find out more about at the meeting.  Here’s what we’re watching:

  • The team at NSABP will be reporting on whether or not oxaliplatin adds to to benefits from 5-FU chemotherapy in stage II colon cancer.
  • Both NSABP and a German group are presenting results as to whether adding oxaliplatin to chemotherapy used with radiation before surgery for rectal cancer increases response to treatment.
  • Other rectal cancer studies will be looking at whether Xeloda® (capecitabine) can safely and effectively be substituted for 5-FU during pre-surgical chemoradiation.
  • What’s the effect of an EGFR inhibitor (Erbitux® or Vectibix) on first-line treatment of advanced colorectal cancer?  Does KRAS status make a difference?  Two studies will report answers.

Besides major work which will be presented during the  oral abstract session session on Saturday, there are over 130 posters covering a variety of cutting-edge colorectal cancer research.  In addition, dozens of other posters look at colorectal cancer screening and prevention and supportive care for patients living with cancer.

  • Do visit us in at the Patient Advocacy Booth if you are in Chicago for ASCO
  • And watch this blog for details as they emerge during ASCO.
  • Also follow us on Twitter: @fightcrc




  1. PGN says

    as a 3x cancer survivor and now just barely surviving the treatment and living with the long term side effects of Oxaliplatin, we need research on dealing with the side effects of the chemo on nerve damage — this is more damage than hands and feet which burn and hurt whether one is sitting down or standing for long periods. I’m talking about the damage done to the colon and intestines itself since that organ requires “nerves” to communicate with the brain to function properly if one is to live a normal and regular life. I am happy to be living but very unhappy about having a “half a life” if that much. Please push hard for research on side effects since the good news we do have more surviving more than 5 years. My first colon cancer was in 2004 stage 4 and 2nd occurrence in 2005 then received radiation/chemo and ever since have developed long term damage.

  2. rob says

    Would like to have someone looking for anything related to Sodium Dichloroacetate in combination with chemo such as Vidaza.

    Think such combinations, and this one in particular, could be a cure for a number of cancers since DCA works based on something common to many cancers, metabolism.

  3. Kate Murphy says

    There are some new drugs in early trials in the posters, but they are very targeted at patients with specific mutations in their tumors.

    I don’t think we will see another “blockbuster” colorectal cancer drug that treats all patients. More and more, drugs are being developed to block pathways known to be mutated in some, but not all, patients. (Like EGFR inhibitors.)

    I do think the oxaliplatin for stage II question is important. Oxaliplatin can cause some pretty debilitating long-term neuropathy. If it doesn’t help in stage II, giving FOLFOX would be a mistake.

    Thanks for the comment. We’ll be sharpening our eyes during the poster sessions.

  4. Jennifer says

    Forgive me but these topics look like small (teensy) potatoes — just tweaking what we know about drugs that have been available for quite some time. Oxi for stage II? Xeloda vs 5fu? Erbitux & KRAS? I’m not on the edge of my seat.

    Maybe next year we’ll get something more promising.

    I do not mean to deprecate the great work you are all doing at C3 — I’m just disappointed at how weak and uninspiring this year’s research output seems to be.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>